Avidity Partners Management LP Sells 3,477,000 Shares of Context Therapeutics Inc. $CNTX

Avidity Partners Management LP lowered its stake in shares of Context Therapeutics Inc. (NASDAQ:CNTX) by 38.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,504,855 shares of the company’s stock after selling 3,477,000 shares during the period. Context Therapeutics accounts for 2.3% of Avidity Partners Management LP’s holdings, making the stock its 11th biggest position. Avidity Partners Management LP owned about 5.99% of Context Therapeutics worth $8,092,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Marshall Wace LLP raised its stake in Context Therapeutics by 7,153.7% in the 4th quarter. Marshall Wace LLP now owns 2,593,198 shares of the company’s stock valued at $3,812,000 after acquiring an additional 2,557,448 shares during the period. State Street Corp raised its stake in Context Therapeutics by 8.5% in the 4th quarter. State Street Corp now owns 165,607 shares of the company’s stock valued at $243,000 after acquiring an additional 13,000 shares during the period. Renaissance Technologies LLC raised its stake in Context Therapeutics by 58.8% in the 4th quarter. Renaissance Technologies LLC now owns 508,329 shares of the company’s stock valued at $747,000 after acquiring an additional 188,202 shares during the period. Blue Owl Capital Holdings LP raised its stake in Context Therapeutics by 0.3% in the 4th quarter. Blue Owl Capital Holdings LP now owns 7,432,906 shares of the company’s stock valued at $10,926,000 after acquiring an additional 25,000 shares during the period. Finally, Citadel Advisors LLC bought a new stake in Context Therapeutics in the 3rd quarter valued at $100,000. Institutional investors own 14.03% of the company’s stock.

Context Therapeutics Price Performance

Shares of NASDAQ CNTX opened at $1.39 on Friday. The stock’s fifty day moving average price is $2.34 and its two-hundred day moving average price is $2.09. Context Therapeutics Inc. has a one year low of $0.56 and a one year high of $3.62. The firm has a market cap of $127.71 million, a price-to-earnings ratio of -3.31 and a beta of 1.61.

Context Therapeutics (NASDAQ:CNTX) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.03. On average, equities analysts anticipate that Context Therapeutics Inc. will post -0.35 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Context Therapeutics in a research note on Monday, April 20th. Wall Street Zen cut Context Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 6th. Guggenheim restated a “buy” rating and issued a $5.00 price target on shares of Context Therapeutics in a research note on Tuesday, March 24th. Piper Sandler increased their price target on Context Therapeutics from $4.00 to $7.00 and gave the company an “overweight” rating in a research note on Tuesday, March 24th. Finally, Lifesci Capital upgraded Context Therapeutics to a “strong-buy” rating in a research note on Monday, February 23rd. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $6.60.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.